Related Experiment Video
Updated: Jun 9, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Malaria chemotherapy: recent advances in drug development
Sandra Gemma1, Valter Travagli, Luisa Savini
1Department of Pharmaceutical and Applied Chemistry, University of Siena, via Aldo Moro 2, 53100 Siena, Italy.
Recent Patents on Anti-Infective Drug Discovery
|August 27, 2010
Summary
Discovering new antimalarial drugs is crucial due to widespread drug resistance. This review examines patents for novel small molecules, natural compounds, and advanced drug delivery systems to combat malaria.
Area of Science:
- * Infectious Diseases and Tropical Medicine
- * Medicinal Chemistry and Drug Discovery
Background:
- * Malaria, caused by Plasmodium parasites, remains a significant global health burden, particularly in endemic areas.
- * Widespread drug resistance in Plasmodium species is a major obstacle to effective malaria control.
- * Artemisinin-based Combination Therapy (ACT) is the current frontline treatment, but emerging resistance is a growing concern.
Purpose of the Study:
- * To review patent literature from 2007 to the present concerning novel antimalarial agents.
- * To identify small molecules and natural compounds targeting asexual Plasmodium parasites.
- * To explore recent patents on innovative dosage forms for antimalarial treatments.
Main Methods:
- * Comprehensive search of patent databases for antimalarial drug development and delivery innovations.
- * Analysis of patents focusing on small molecules and natural products against Plasmodium asexual stages.
- * Review of patents related to novel drug formulations and delivery systems for antimalarial therapies.
Main Results:
- * Significant patent activity in the development of novel small molecules and natural compounds as antimalarial candidates.
- * Emerging trends in targeting drug-resistant Plasmodium falciparum strains.
- * Innovations in drug delivery systems, including non-conventional dosage forms, to improve antimalarial efficacy and patient compliance.
Conclusions:
- * The patent landscape indicates a strong R&D focus on discovering new antimalarial therapies to address resistance.
- * Novel chemical entities and natural products show promise for future malaria treatment.
- * Advancements in drug formulation and delivery are critical for enhancing the effectiveness of existing and new antimalarial drugs.
More Related Videos
05:28Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
Published on: May 12, 2022
09:13Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Related Concept Videos
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).